JDRF announces 2008 Spring Research Re... ( The Juvenile Diabetes Research Found...)

JDRF announces 2008 Spring Research Review Award

Date:5/22/2008

The Juvenile Diabetes Research Foundation recently awarded its top honors to three noted scientists. The awards were presented at the 2008 Spring Research Review Awards Dinner.

The David Rumbough Award for Scientific Excellence was established in 1974 by the actress Dina Merrill, in honor of her late son, David. It is the highest honor JDRF awards, and is presented annually to researchers for outstanding achievement and commitment to diabetes research and for their service to JDRF. Michael Brownlee, MD, and Michael German, MD, received the 2008 Rumbough Award.

The Gerold & Kayla Grodsky Basic Research Scientist Award is presented annually to a basic research scientist who has made outstanding contributions to diabetes research. JDRF established the award in 1993 to honor the contributions of Dr. Grodsky's diabetes research at University of California at San Francisco (UCSF) over four decades. This years recipient is Maike Sander, MD.

Of the presentation, Dina Merrill said she was honored to join with you tonight in the presentation of the David Rumbough Award for Scientific Excellence, which was established in honor of my late, beloved son, David. He would have been very pleased to know that research towards a cure is progressing rapidly and improving the lives of so many. Keep up the good work.

Michael Brownlee, MD, the Anita and Jack Saltz Professor of Diabetes Research at Albert Einstein College of Medicine is one of the most respected and influential scientists in his field. He is noted for his innovative approach to understanding the biochemical basis of diabetic complications. Internationally recognized for his research, Dr. Brownlee discovered a novel molecular pathway linking hyperglycemia to diabetic retinopathy, a complication of the disease.

Dr. Brownlee is also the Director of the JDRF International Center for Diabetic Complications Research. All of the projects in this Center share an overriding aim
'/>"/>

Contact: Jillian Lubarsky
jlubarsky@jdrf.org
212-479-7626
Juvenile Diabetes Research Foundation International
Source:Eurekalert

0

GOOD

Page: 1 2
Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories

Post Your Comments:

(Date:8/20/2008)...r-old Contestant Wins Trip to Little League Baseba... The National Spit Tobacco Education,Program (NSTE...st today,and encouraged young baseball players to...ddiction and the health risks of using tobacco pro...year,s slogan contest winner is,Joe Reck, a nine-y...

(Date:8/20/2008)...cently enacted Medicare Improvement Law immediatel...re Advantage insurance companies .../PRNewswire/ -- When the House and Senate,overrode...gislation,protecting Medicare beneficiaries, they ...e Advantage plans during one of the busiest months...

(Date:8/20/2008)...T CREEK, Calif., Aug. 20 /PRNewswire-FirstCall/ --... reported preliminary income from,continuing opera...f $27.5,million, or $0.76 per diluted share, inclu...er diluted share, related to provisions for store,... a 6.8 percent increase,compared with income from ...

(Date:8/20/2008)...FIELD, Mich., Aug. 20 /PRNewswire/ -- WXYZ- TV/Cha...llness Promotion will give thousands of,Detroit me...ALTHY LIVING,FOR KIDS" program. This year the prog....m. to 5 p.m. at the Charles H. Wright Museum of A...77, "Healthy Living for Kids",has provided free im...

[0] Slogan Contest Educates Young Baseball Players About the Dangers of Tobacco Use [0] Medicare Advantage Plans Struggle to Comply With New Federal Law [0] Longs Drug Stores Corporation Reports Second Quarter Results [0] WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History

...ndia's biggest drugmaker Ranbaxy Laboratories Ltd ...ply agreement with Janssen-Ortho Inc (JOI) for a g...n the Canadian market. // The agreement was signe...diary, Ranbaxy Pharmaceuticals Canada Inc (RPCI) a...

...nternational experts from the worlds of academia, ... next month to discuss how state-of-the-art// comm...le and affordable. E-health is an emerging field...rvices and information such as electronic medical ...

...orway has granted $80 million to the National Rura...ion, child and maternal health programmes.// The ...he two programme partners - for specific activitie...a and Norway also launched a multi-partner initiat...

...iming at empowering transgenders and those affecte...) was launched here today. // 'Tai Vizhuthugal' (...ther hundreds of transgenders from Coimbatore, Mad... an aim at empowering and enabling the community t...

Other Medicine News:Health News:Delhi to Host E-health Global Meet Next Month 2 Health News:Norway Grants $80 mn to India's Health Mission 2

Ranbaxy Signs Licensing, Supply Agreement for Canadian Market Delhi to Host E-health Global Meet Next Month Norway Grants $80 mn to India's Health Mission Community Based Organisation for Transgenders and HIV Affected

(Date:8/17/2008)..., Aug. 17 /Xinhua-- Pharmax...he first pivotal Phase 3,clinical trial of Bronchi...eted enrolment., The first efficacy data from the...t half of 2009. The trial commenced its dosing pha...target of 250 subjects in June,2008 and closed tod...

(Date:8/14/2008)...ng antibody (BiTE) showing clinical benefit in can...cells to recognize and attack ...Newswire-FirstCall/ -- Micromet, Inc.,(Nasdaq: MI..., proprietary,antibodies for the treatment of canc...nounced publication of a Phase 1 clinical study(1)...

(Date:8/13/2008).../- As biotechnology,pharma... move clinical,trials beyond their own borders to ...rope and South America, complicated regulatory env...iness, according to an analysis by,Aon Corporation...p provides,those companies a visual representation...

(Date:8/13/2008)...ug. 13 /- Today positron emission,tom...gly helpful oncology,tool for diagnosis, staging a...ion imaging technology emitting a radioactive trac...acer gathers in abnormal tissue. As a,result, the ... appears as a,"hot spot.", The use of multiple im...

Breaking Medicine Technology:Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment 2 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 2 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 3 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 4 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 5 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 6 Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 2 Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 3 Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 4 Are PET Scans Beneficial During Cancer Diagnosis, Staging and Monitoring? 2 Milkweeds evolutionary approach to caterpillars 3A Counter appetite with fast repair 4149 1 Milkweeds evolutionary approach to caterpillars 3A Counter appetite with fast repair 4149 2 Measuring the stress of forested areas 4148 1 Measuring the stress of forested areas 4148 2 Measuring the stress of forested areas 4148 3 Pharmasmart International Taps Top Executive Ashton Maaraba to Head Global Sales and Marketing 6666 1 Pharmasmart International Taps Top Executive Ashton Maaraba to Head Global Sales and Marketing 6666 2 Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2686 1 Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2686 2 Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2686 3

[1] Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment [0] Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab [0] Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders [0] Are PET Scans Beneficial During Cancer Diagnosis, Staging and Monitoring?

...), a,biopharmaceutical company specializing in dev...Lipoprotein (HDL), often called,"good cholesterol,...s of the Phase I/II Clinical Trial of its lead pro...ent of dyslipidemia and,heart disease. , A detaile...,blood chemistry and blood pressure measurements w...

...2007, SAN DIEGO, and SEOUL, South Korea, April 13,...Inc. and LG Life,Sciences, Ltd., presented data fr... retains potency against multiple mutant strains o...amivudine,adefovir, entecavir or telbivudine, dur...ng of the European Association for the Study,of th...

Other Medicine Technology:Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical,Trial Data 2 Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical,Trial Data 3 ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants 2 ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants 3 ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants 4 ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants 5 ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants 6

Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical,Trial Data ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants

...ally read, qualitative immunochromatographic metho...a bacterium that grows in the stomach and is assoc...ancers. FlexSure HP, available for use with either...ian with the opportunity to perform "on-the-spot" ...

OraQuick is an FDA approved rapid point-of-care fingerstick and venipuncture whole blood test used to aid in the diagnosis of HIV-1 infection. This CLIA waived test, which detects the presence of ant

Rapid Infectious Mononucleosis Heterophile Antibody (IgM) Test

...Mononucleosis test is designed to detect the IgM h...ood. The QuickVue+ Infectious Mononucleosis assay ...ive a greater sensitivity and specificity than sim...ocytes. QuickVue+ Infectious Mononucleosis is a ra...

Medicine Products:

FlexSure HP OraQuick Rapid HIV-1 Antibody Test BioSign® Mono - Rapid Infectious Mononucleosis Heterophile Antibody (IgM) Test QuickVue+ Infectious Mononucleosis test

JDRF announces 2008 Spring Research Re...( The Juvenile Diabetes Research Found...),Health